Introduction
Mammary gland development is under the control of a wide variety of factors that include steroid hormones (estradiol, progesterone, and glucocorticoids), peptide hormones with anabolic properties (insulin, and growth hormone) or with specific effects upon the mammary tissue (prolactin, lactogenic hormone, and relaxin), thyroid hormones, and local growth factors [1] . Several data also underlined a possible modulatory role for melatonin in mammary gland growth [2] .
Melatonin is a major secretory product of the pineal gland. Its robust circadian rhythm which is high during the night and low during the day is well-documented in animals and humans. In mice, melatonin displays a circadian rhythm with a narrow peak at midnight [3, 4] . This indoleamine is an important hormonal signal for the regulation of animal and human physiology as well as being an endogenous free radical scavenger [5] . In addition to its well-known modulatory actions on sleep and seasonal reproductive responses [5] , melatonin has also been shown to influence activities of the endogenous circadian clock [6, 7] 1 . The antiproliferative actions of melatonin on the estrogen-responsive breast cancer have been widely studied [8] [9] [10] [11] [12] . These antiproliferative actions of melatonin are effective at physiological doses and depend on the rate of proliferation and the pattern of exposure to melatonin [13] . In turn, tumor development and growth decrease melatonin production by the pineal gland [14] . The mechanism involved in the oncostatic effects of melatonin remains unknown [10] , and two main mechanisms may be involved in these effects, i.e. antioxidant role and interaction with specific receptors. Melatonin acts as a free radical scavenger [15, 16] , and this feature should be considered to explain its antitumoral effects on mammary cancer. The hydroxyl radical is the most toxic-free radical against nuclear DNA, and it was reported that melatonin protects against oxidative damage to DNA both in vivo or in vitro [17] . However, specific 125 I-melatonin binding sites with nanomolar affinity to membrane preparations of murine mammary tissue have been reported [1] . This nanomolar affinity contrasts with the picomolar affinity reported elsewhere in membranes from other tissues. In turn, nuclear receptors for melatonin have been characterized in other tissues such as rat liver [18] .
A possible modulatory role of melatonin on mammary gland may comprise two kinds of phenomena. could affect mammary gland development indirectly, by changing the circulating levels of some pituitary and gonadal hormones that control mammogenesis. A second mechanism by which melatonin may influence mammary growth may depend on a direct action of the indoleamine in mammary tissue, either through its antioxidant role or through nuclear receptors. The objective of the present work was to characterize the existence of 125 I-melatonin binding sites in purified nuclei from mouse mammary glands and to assess whether these binding sites change with the photoperiod.
Materials and methods Chemicals
Tris, sucrose, deoxyribonuclease (DNase), proteinase K (PK), melatonin, N-acetylserotonin, 5-methoxytryptamine were purchased from Sigma-Aldrich (Madrid, Spain).
2-
125 I-iodomelatonin with a specific activity of 2200 Ci/ mmol was purchased from Pelkin-Elmer Life Science, Inc. (Boston, MA, USA). All other reagents were of the highest purity available.
Animals and tissue preparation
Female Swiss mice aged 4 wk were maintained in the University's animal facility, housed in separate cages (four to five animals per cage), and exposed to a 12:12 hr light/dark cycle at 22°C. Animals received tap water and a standard pellet diet ad libitum. In some experiments, a group of animals was maintained under continuous light for 2 wk before being used for the experiments.
Animals maintained in normal photoperiod were divided into two groups: one group was killed by decapitation at midday and the other 2 hr before light on (07.00) 2 . Animals maintained under continuous light were killed at an equivalent midday time. In all cases, the mammary glands were dissected, frozen on liquid nitrogen and stored at )80°C until assayed. On the day of the experiment, the mammary glands were weighed and their cell nuclei isolated [18, 19] . Briefly, glandular tissue (0.9-1.2 g) was homogenized in 3 mL of A buffer (10 mm Tris-HCl, pH 8, 3 mm CaCl 2 , 2 mm MgCl 2 , 0.5 mm dithiothreitol, 0.3 m sucrose, 0.15% Triton X-100) with a glass/Teflon homogenizer (Stuart Scientific, UK), and layered over 3 mL of A buffer containing 0.4 m sucrose. The samples were then centrifuged at 2500 g for 10 min. The resulting nuclear pellet was gently resuspended, without vortexing, in 1 mL of A buffer and centrifuged once again. All the procedures described above were performed at 4°C. The nuclei were resuspended in 1 mL of B buffer (50 mm Tris-HCl, pH 8), disrupted using a Polytron homogenizer (Kinematica, Switzerland) 3 (7s, set point 9), and frozen to )80°C until the binding assay was performed (usually within 48 hr).
Binding assay
Preliminary binding conditions including incubation time, protein concentration, pH and temperature for specific 125 I-melatonin binding were developed for these experiments as described elsewhere [17] . 125 I-melatonin was diluted in the incubation medium (50 mm Tris-HCl, pH 7.4), and drugs were dissolved in 0.25% ethanol; at this concentration it was found that ethanol does not interfere with binding kinetics. 4 Purified nuclei homogenates were resuspended in the incubation medium, yielding a protein concentration of about 1 mg/mL, and preincubated at 37°C for 20 min in the presence of deoxyribonuclease (2 lg/mL). Binding was initiated by the addition of 250 lL of the preincubated homogenates to 500 lL Eppendorf tubes containing 5 lL 125 I-melatonin (40-800 pm) and 5 lL of drugs or vehicle. The binding of 125 I-melatonin was measured in triplicate after incubation at 0°C for 1 hr. At the end of incubation, the reaction was stopped by centrifugation in a microfuge; pellets were washed twice with ice-cold Tris buffer (50 mm Tris-HCl, pH 7.4) after decanting the supernatant. Non-specific binding was defined as binding in the presence of 500 nm unlabeled melatonin. Specific binding of 125 I-melatonin was calculated as the difference between total binding and non-specific binding.
Binding data at equilibrium were obtained by two different processes: (1) saturation experiments, in which the concentration of radioactive ligand varied, and (2) competition experiments, in which the concentration of radioligand remained the same, while the concentration of unlabeled ligand varied; in this case, the specific activity of 125 I-melatonin was recalculated for each concentration of ligand. Data from saturation and competition experiments were analyzed using the Ligand-PC (Kell software, Biosoft, Cambridge, UK), which yields the equilibrium binding constants (B max is the maximal number of binding sites, K D the dissociation constant, and IC 50 ). The protein concentration in the assay was determined according to the method of Bradford [20] . Data are expressed as mean ± S.E.M. from closely correlated triplicates. All experiments were carried out at least three times.
Results
The binding of 125 I-melatonin to mammary glands cell nuclei was rapid, saturable and reversible. The equilibrium dissociation constant (K D ) and maximum number of binding sites (B max ) were analyzed by Scatchard transformation. Under normal photoperiod, the kinetic analysis from the binding to cell nuclei obtained during the dark period showed K D ¼ 185 ± 36 pm and B max ¼ 6.24 ± 0.4 fmol/mg protein (Fig. 1) . Scatchard transformation of the binding data to nuclei obtained during the day in a normal photoperiod showed K D ¼ 562 ± 57 nm and B max ¼ 7.56 ± 0.4 pmol/mg protein (Fig. 1) . These data indicate a significant decrease in the affinity of melatonin for its nuclear receptor during the day. When animals were maintained under continuous light, analysis of the binding data showed K D ¼ 1.43 ± 0.2 nm and B max ¼ 24.75 ± 3.5 fmol/mg protein (Fig. 1) . In all cases, Hill plot of the data yield n H values between 0.96 and 0.98, indicating the presence of a single class of binding sites.
In competition experiments, the specific binding of 125 I-melatonin to mammary gland cell nuclei was inhibited by increasing concentration of unlabeled melatonin, yielding IC 50 values of 284 ± 68 pm, 920 ± 76 nm and 946 ± 62 pm in animals killed under normal photoperiod at night, at day, and in animals under continuous light, respectively (Fig. 2) .
Discussion
The data from this study constitute the first description of the existence of melatonin binding sites in cell nuclei of mouse mammary gland. In previous experiments, 125 I-melatonin binding to murine mammary glands was reported, showing the existence of a 24 hr rhythm in both receptor affinity and density [21] . However, cold melatonin displaced 125 I-melatonin from these membrane preparations very weakly, exhibiting a K i within the micromolar range [21] . By contrast, our results show a high-affinity binding for melatonin in nuclei at night, in the same range as that described in nuclei from rat liver [18] . The K D value obtained for melatonin binding to nuclei at night correlates well with plasma levels of the indoleamine at this time, thus allowing melatonin binding sites to be recognized by circulating melatonin. However, K D values obtained at day, in the high nanomolar range, could never be saturated by plasma melatonin. Only if melatonin is accumulated into the mammary gland, enough levels of the indoleamine may be attained to bind and activate these nuclear receptors. In this regard, it was suggested that mouse mammary gland accumulates melatonin [1] , and we confirmed these data showing that melatonin content in these glands reaches two orders of magnitude more than its plasma concentration during the day (Coto-Monksa, Unpublished) 5
. One explanation for the high levels of melatonin present in the mouse mammary gland is the high content of adipose tissue that these glands contain, which may serve as a storing pool of the indoleamine. The existence of a high content of melatonin is not restricted to the mammary glands, as recent reports have shown comparable levels of melatonin in other tissues [22] , whereas high amounts of the indoleamine were present in biological fluids such as bile and cerebrospinal fluid [23, 24] .
Previous data showed a diurnal rhythm in the binding capacity of 125 I-melatonin to membrane preparations in different tissues [25] [26] [27] [28] [29] [30] , although this is the first report showing daytime differences in the nuclear binding of 125 I-melatonin. Nuclear binding of melatonin displays two main characteristics: there is a day-night difference in the binding affinity, and the daytime affinity is reduced by continuous light exposure. The results from studies on melatonin binding sites and the diurnal responses of animals to melatonin administration have shown that sensitivity to melatonin appears to be inversely related to the endogenous levels of the indoleamine. The inhibitory effect of melatonin administration in the afternoon, but not in the morning, on the neuroendocrine-reproductive axis [31] was related to alterations in the response of melatonin receptors. Therefore, high levels of melatonin induce receptor desensitization, and low levels of the indoleamine increases binding affinity. Our results suggest that when animals were maintained in continuous light and thus, melatonin production by the pineal gland was reduced, melatonin binding affinity increases significantly compared with the daytime data from animals under normal photoperiod. Accordingly, these findings may suggest that melatonin content in the mouse mammary gland was also reduced by light treatment. However, as we did not measure melatonin levels in these conditions, we cannot confirm this hypothesis.
The significance of the nuclear binding sites of melatonin in mouse mammary glands should be further explored, although a relationship between these sites and genomic effects of the indoleamine is suggested. Increasing evidence supports a direct action of melatonin in mammary tissue, including its effects on murine mammary gland growth [2, 32] . A reduction in both serum estradiol levels and thymidine incorporation into DNA was found in melatonin-treated C3H/Jax mice [33] . These findings were positively correlated with the weak mammary gland development seen in these mice. Melatonin administration to BALBc mice decreased the DNA content of the mammary glands with a reduced development [34] . Transgenic mice carrying the N-ras proto-oncogene were also used to test the effects of melatonin treatment on their mammary glands. Pharmacological doses of melatonin resulted in a lower density of hyperplasic alveolar nodules in mammary glands of these mice, and a significant reduction in N-ras expression [35] . As a result of the treatment, melatonin prevented the development of epithelial cell atypia and mammary adenocarcinomas. Many data also support the oncostatic effects of melatonin in preventing or delaying breast cancer development [36] [37] [38] [39] . Melatonin displays anti-angiogenic activity [40] , and exerts oncostatic effects through its nuclear receptor [41, 42] . Moreover, melatonin production and rhythmicity decreases as a result of a malignant tumor growth [14] . Thus, the presence of nuclear melatonin binding sites in the murine mammary gland may account for the antiproliferative effect of the indoleamine. Melatonin is also a broad-spectrum antioxidant involved in cellular protection against free radical attack. Melatonin directly scavenges both reactive oxygen and nitrogen species [43] , which likely account for at least some of the protective actions of melatonin under conditions of high oxidative stress. Nevertheless, additional receptor-dependent actions of melatonin, e.g. on antioxidative enzyme induction [44] , seem to contribute to the overall antioxidant protection by the indoleamine. Thus, the presence of high amounts of melatonin, together with its nuclear binding sites in mouse mammary gland, may contribute to the defense against free radical attack to the lipid-enriched mammary tissue.
In conclusion, we confirm the existence of two classes of binding sites for melatonin in cell nuclei of mouse mammary glands, which may be regulated by the photoperiod. The results also support the hypothesis of a regulatory role of melatonin on the mammary gland in which melatonin downregulates its own binding sites. High levels of the indoleamine are necessary for the interaction with its receptor during the day. Although melatonin accumulation in the adipose tissue of the mammary gland has been proposed, its significance and relationship to the nuclear effects of melatonin require further investigation.
